Sarvenaz Keshmiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarvenaz Keshmiri has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Jean-François Adam
Univ. Grenoble Alpes, INSERM, UA07 STROBE, 2280 rue de la piscine, Saint-Martin d'Hères, 38400, France.
6 shared publications - Raphaël Serduc
INSERM, U836, F-38043 Grenoble, France
4 shared publications Gaëtan Lemaire
Univ. Grenoble Alpes, INSERM, UA07 STROBE, 2280 rue de la piscine, Saint-Martin d'Hères, 38400, France
3 shared publications- Paolo Pellicioli
Biomedical Beamline ID17, European Synchrotron Radiation Facility, 38043 Grenoble, France
3 shared publications Raphaël Serduc
Univ. Grenoble Alpes, INSERM, UA07 STROBE, 2280 rue de la piscine, Saint-Martin d'Hères, 38400, France
3 shared publicationsCamille Verry
Univ Grenoble Alpes, INSERM, STROBE UA07, 2280 rue piscine, F-38610 Gieres, France
2 shared publications
Latest Publications
- Open Access
Synchrotron‐generated microbeams as a radiosurgical alternative for drug‐resistant epilepsies: Proof of concept in a mouse model of mesiotemporal lobe epilepsy
Objective: One‐third of patients with epilepsy, particularly those with mesial temporal lobe epilepsy (MTLE), remain resistant to medication. Resective surgery, the gold standard, is highly invasive and carries significant risks. Here, using a mouse model, we explored the potential of microbeam radiation therapy (MRT), a new technique based on the spatial microfractionation of high‐flux X‐rays, as a non‐invasive alternative for treating MTLE. Methods: MTLE was modeled in male C57BL6/J mice via unilateral kainate injection in the dorsal hippocampus. Mice with magnetic resonance imaging (MRI)–validated hippocampal sclerosis (HS) were irradiated at the European Synchrotron Radiation Facility (ESRF) using MRT with either a single trajectory (peak doses = 125–500 Gy) or multiple trajectories (2 or 5 ports at a cumulated peak dose of 125 Gy at the target). Their focal seizures were then monitored with use of electroencephalography (EEG) during 8 weeks, upon which immunochemistry was performed to assess potential tissular toxicity. Results: Anteroposterior 1‐port MRT significantly reduced EEG‐recorded focal seizures at 125 and 250 Gy, in a dose‐dependent manner. However, increased mortality was observed at 500 Gy. Immunohistolabeling revealed neuronal loss (revealed by NeuN staining), microgliosis (revealed by Iba1 straining), and astrogliosis (revealed by GFAP staining) limited to the microbeam tracks at all doses in the injected hippocampus and adjacent brain structures (e.g., cortex). Five‐port MRT with a peak dose of 125 Gy at the target improved the antiepileptic effect, whereas no significant tissue alterations outside the microbeam tracks were detected by histological assessment. Significance: This proof‐of‐concept study highlights MRT as a promising non‐invasive therapy for drug‐resistant focal epilepsies with optimal peak doses of 125–250 Gy, and it suggests that distributing the dose through multiple angles optimizes the therapeutic effect. MRT could provide a safer alternative to surgery, warranting further investigations.
Open AccessSynchrotron‐generated microbeams as a radiosurgical alternative for drug‐resistant epilepsies: Proof of concept in a mouse model of mesiotemporal lobe epilepsy
Objective: One‐third of patients with epilepsy, particularly those with mesial temporal lobe epilepsy (MTLE), remain resistant to medication. Resective surgery, the gold standard, is highly invasive and carries significant risks. Here, using a mouse model, we explored the potential of microbeam radiation therapy (MRT), a new technique based on the spatial microfractionation of high‐flux X‐rays, as a non‐invasive alternative for treating MTLE. Methods: MTLE was modeled in male C57BL6/J mice via unilateral kainate injection in the dorsal hippocampus. Mice with magnetic resonance imaging (MRI)–validated hippocampal sclerosis (HS) were irradiated at the European Synchrotron Radiation Facility (ESRF) using MRT with either a single trajectory (peak doses = 125–500 Gy) or multiple trajectories (2 or 5 ports at a cumulated peak dose of 125 Gy at the target). Their focal seizures were then monitored with use of electroencephalography (EEG) during 8 weeks, upon which immunochemistry was performed to assess potential tissular toxicity. Results: Anteroposterior 1‐port MRT significantly reduced EEG‐recorded focal seizures at 125 and 250 Gy, in a dose‐dependent manner. However, increased mortality was observed at 500 Gy. Immunohistolabeling revealed neuronal loss (revealed by NeuN staining), microgliosis (revealed by Iba1 straining), and astrogliosis (revealed by GFAP staining) limited to the microbeam tracks at all doses in the injected hippocampus and adjacent brain structures (e.g., cortex). Five‐port MRT with a peak dose of 125 Gy at the target improved the antiepileptic effect, whereas no significant tissue alterations outside the microbeam tracks were detected by histological assessment. Significance: This proof‐of‐concept study highlights MRT as a promising non‐invasive therapy for drug‐resistant focal epilepsies with optimal peak doses of 125–250 Gy, and it suggests that distributing the dose through multiple angles optimizes the therapeutic effect. MRT could provide a safer alternative to surgery, warranting further investigations.
- Open Access
- 7 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 28959
Recent advances in film dosimetry for quality assurance in microbeam radiation therapy
Microbeam Radiation Therapy (MRT) is currently on the verge of entering the clinical phase, necessitating robust quality assurance (QA) with appropriate dosimeters to ensure patient safety. However, MRT dosimetry presents significant challenges due to its intrinsic characteristics, including steep dose gradients with alternating high and low dose regions-referred to as peaks and valleys (valley doses comprising only 5-7% of peak doses)-micrometric resolution requirements, the use of low-to-medium energy X-rays and extremely high dose rates of up to 16 kGy/s. Currently, Gafchromic films are considered the gold standard for patient QA. Previous studies have reported discrepancies of 10-30% between measured and calculated peak and valley doses. This study aimed to evaluate four types of films (EBT-3, EBT-XD, MD-V3, and HD-V2) to determine the most suitable option for MRT QA. To support dosimetric benchmarking, the microDiamond detector was used as the reference for MRT measurements, and the ionization chamber for broad beam reference dosimetry. Discrepancies were observed between calculated and film-measured peak and valley doses, and several hypotheses were proposed to explain these differences. Possible causes include simplifications in dose calculation engines, intrinsic limitations of the films, uncertainties in experimental setups, and variations in readout methods. The study suggests that MD-V3 may be the most suitable film for MRT dosimetry, offering a dynamic range that effectively covers both peak and valley doses.
- 7 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 28959
Open AccessRecent advances in film dosimetry for quality assurance in microbeam radiation therapy
Microbeam Radiation Therapy (MRT) is currently on the verge of entering the clinical phase, necessitating robust quality assurance (QA) with appropriate dosimeters to ensure patient safety. However, MRT dosimetry presents significant challenges due to its intrinsic characteristics, including steep dose gradients with alternating high and low dose regions-referred to as peaks and valleys (valley doses comprising only 5-7% of peak doses)-micrometric resolution requirements, the use of low-to-medium energy X-rays and extremely high dose rates of up to 16 kGy/s. Currently, Gafchromic films are considered the gold standard for patient QA. Previous studies have reported discrepancies of 10-30% between measured and calculated peak and valley doses. This study aimed to evaluate four types of films (EBT-3, EBT-XD, MD-V3, and HD-V2) to determine the most suitable option for MRT QA. To support dosimetric benchmarking, the microDiamond detector was used as the reference for MRT measurements, and the ionization chamber for broad beam reference dosimetry. Discrepancies were observed between calculated and film-measured peak and valley doses, and several hypotheses were proposed to explain these differences. Possible causes include simplifications in dose calculation engines, intrinsic limitations of the films, uncertainties in experimental setups, and variations in readout methods. The study suggests that MD-V3 may be the most suitable film for MRT dosimetry, offering a dynamic range that effectively covers both peak and valley doses.
- Open Access
Neuro-Oncologic Veterinary Trial for the Clinical Transfer of Microbeam Radiation Therapy: Acute to Subacute Radiotolerance after Brain Tumor Irradiation in Pet Dogs
Synchrotron Microbeam Radiation Therapy (MRT) has repeatedly proven its superiority compared with conventional radiotherapy for glioma control in preclinical research. The clinical transfer phase of MRT has recently gained momentum; seven dogs with suspected glioma were treated under clinical conditions to determine the feasibility and safety of MRT. We administered a single fraction of 3D-conformal, image-guided MRT. Ultra-high-dose rate synchrotron X-ray microbeams (50 µm-wide, 400 µm-spaced) were delivered through five conformal irradiation ports. The PTV received ~25 Gy peak dose (within microbeams) per port, corresponding to a minimal cumulated valley dose (diffusing between microbeams) of 2.8 Gy. The dogs underwent clinical and MRI follow-up, and owner evaluations. One dog was lost to follow-up. Clinical exams of the remaining six dogs during the first 3 months did not indicate radiotoxicity induced by MRT. Quality of life improved from 7.3/10 [±0.7] to 8.9/10 [±0.3]. Tumor-induced seizure activity decreased significantly. A significant tumor volume reduction of 69% [±6%] was reached 3 months after MRT. Our study is the first neuro-oncologic veterinary trial of 3D-conformal Synchrotron MRT and reveals that MRT does not induce acute to subacute radiotoxicity in normal brain tissues. MRT improves quality of life and leads to remarkable tumor volume reduction despite low valley dose delivery. This trial is an essential step towards the forthcoming clinical application of MRT against deep-seated human brain tumors.
Open AccessNeuro-Oncologic Veterinary Trial for the Clinical Transfer of Microbeam Radiation Therapy: Acute to Subacute Radiotolerance after Brain Tumor Irradiation in Pet Dogs
Synchrotron Microbeam Radiation Therapy (MRT) has repeatedly proven its superiority compared with conventional radiotherapy for glioma control in preclinical research. The clinical transfer phase of MRT has recently gained momentum; seven dogs with suspected glioma were treated under clinical conditions to determine the feasibility and safety of MRT. We administered a single fraction of 3D-conformal, image-guided MRT. Ultra-high-dose rate synchrotron X-ray microbeams (50 µm-wide, 400 µm-spaced) were delivered through five conformal irradiation ports. The PTV received ~25 Gy peak dose (within microbeams) per port, corresponding to a minimal cumulated valley dose (diffusing between microbeams) of 2.8 Gy. The dogs underwent clinical and MRI follow-up, and owner evaluations. One dog was lost to follow-up. Clinical exams of the remaining six dogs during the first 3 months did not indicate radiotoxicity induced by MRT. Quality of life improved from 7.3/10 [±0.7] to 8.9/10 [±0.3]. Tumor-induced seizure activity decreased significantly. A significant tumor volume reduction of 69% [±6%] was reached 3 months after MRT. Our study is the first neuro-oncologic veterinary trial of 3D-conformal Synchrotron MRT and reveals that MRT does not induce acute to subacute radiotoxicity in normal brain tissues. MRT improves quality of life and leads to remarkable tumor volume reduction despite low valley dose delivery. This trial is an essential step towards the forthcoming clinical application of MRT against deep-seated human brain tumors.
- Open Access
- 28 February 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 30, 100565
Treatment planning with high-resolution 3D dose maps in preclinical and translational synchrotron microbeam radiation therapy
- 28 February 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 30, 100565
Open AccessTreatment planning with high-resolution 3D dose maps in preclinical and translational synchrotron microbeam radiation therapy
- Open Access
- 10 October 2023
- Published by International Union of Crystallography (IUCr) in Journal of Synchrotron Radiation
- Vol. 30 (6) , 1076-1085
Monocrystalline diamond detector for online monitoring during synchrotron microbeam radiotherapy
Microbeam radiation therapy (MRT) is a radiotherapy technique combining spatial fractionation of the dose distribution on a micrometric scale, X-rays in the 50–500 keV range and dose rates up to 16 × 103 Gy s−1. Nowadays, in vivo dosimetry remains a challenge due to the ultra-high radiation fluxes involved and the need for high-spatial-resolution detectors. The aim here was to develop a striped diamond portal detector enabling online microbeam monitoring during synchrotron MRT treatments. The detector, a 550 µm bulk monocrystalline diamond, is an eight-strip device, of height 3 mm, width 178 µm and with 60 µm spaced strips, surrounded by a guard ring. An eight-channel ASIC circuit for charge integration and digitization has been designed and tested. Characterization tests were performed at the ID17 biomedical beamline of the European Synchrotron Radiation Facility (ESRF). The detector measured direct and attenuated microbeams as well as interbeam fluxes with a precision level of 1%. Tests on phantoms (RW3 and anthropomorphic head phantoms) were performed and compared with simulations. Synchrotron radiation measurements were performed on an RW3 phantom for strips facing a microbeam and for strips facing an interbeam area. A 2% difference between experiments and simulations was found. In more complex geometries, a preliminary study showed that the absolute differences between simulated and recorded transmitted beams were within 2%. Obtained results showed the feasibility of performing MRT portal monitoring using a microstriped diamond detector. Online dosimetric measurements are currently ongoing during clinical veterinary trials at ESRF, and the next 153-strip detector prototype, covering the entire irradiation field, is being finalized at our institution.
- 10 October 2023
- Published by International Union of Crystallography (IUCr) in Journal of Synchrotron Radiation
- Vol. 30 (6) , 1076-1085
Open AccessMonocrystalline diamond detector for online monitoring during synchrotron microbeam radiotherapy
Microbeam radiation therapy (MRT) is a radiotherapy technique combining spatial fractionation of the dose distribution on a micrometric scale, X-rays in the 50–500 keV range and dose rates up to 16 × 103 Gy s−1. Nowadays, in vivo dosimetry remains a challenge due to the ultra-high radiation fluxes involved and the need for high-spatial-resolution detectors. The aim here was to develop a striped diamond portal detector enabling online microbeam monitoring during synchrotron MRT treatments. The detector, a 550 µm bulk monocrystalline diamond, is an eight-strip device, of height 3 mm, width 178 µm and with 60 µm spaced strips, surrounded by a guard ring. An eight-channel ASIC circuit for charge integration and digitization has been designed and tested. Characterization tests were performed at the ID17 biomedical beamline of the European Synchrotron Radiation Facility (ESRF). The detector measured direct and attenuated microbeams as well as interbeam fluxes with a precision level of 1%. Tests on phantoms (RW3 and anthropomorphic head phantoms) were performed and compared with simulations. Synchrotron radiation measurements were performed on an RW3 phantom for strips facing a microbeam and for strips facing an interbeam area. A 2% difference between experiments and simulations was found. In more complex geometries, a preliminary study showed that the absolute differences between simulated and recorded transmitted beams were within 2%. Obtained results showed the feasibility of performing MRT portal monitoring using a microstriped diamond detector. Online dosimetric measurements are currently ongoing during clinical veterinary trials at ESRF, and the next 153-strip detector prototype, covering the entire irradiation field, is being finalized at our institution.
- Open Access
- 12 April 2022
- Published by Wiley in Medical Physics
- Vol. 49 (6) , 3999-4017
A high‐resolution dose calculation engine for X‐ray microbeams radiation therapy
Background: Microbeam radiation therapy (MRT) is a treatment modality based on spatial fractionation of synchrotron generated X‐rays into parallel, high dose, microbeams of a few microns width. MRT is still an underdevelopment radiosurgery technique for which, promising preclinical results on brain tumors and epilepsy encourages its clinical transfer.Purpose: A safe clinical transfer of MRT needs a specific treatment planning system (TPS) that provides accurate dose calculations in human patients, taking into account the MRT beam's properties (high‐dose gradients, spatial fractionation, polarization effects). So far, the most advanced MRT TPS, based on a hybrid dose calculation algorithm, is limited to a macroscopic rendering of the dose and does not account for the complex dose distribution inherent to MRT if delivered as conformal irradiations with multiple incidences. For overcoming these limitations, a multi‐scale full Monte‐Carlo calculation engine called penMRT has been developed and benchmarked against two general‐purpose Monte Carlo (MC) codes: penmain based on PENELOPE and Gate based on Geant4.Methods: PenMRT, is based on the PENELOPE (2018) MC code, modified to take into account the voxelized geometry of the patients (computed tomography [CT]‐scans) and is offering an adaptive micrometric dose calculation grid independent of the CT size, location, and orientation. The implementation of the dynamic memory allocation in penMRT, makes the simulations feasible within a huge number of dose scoring bins. The possibility of using a source replication approach to simulate arrays of microbeams, and the parallelization using OpenMPI have been added to penMRT in order to increase the calculation speed for clinical usages. This engine can be implemented in a TPS as a dose calculation core.Results: The performance tests highlight the reliability of penMRT to be used for complex irradiation conditions in MRT. The benchmarking against a standard PENELOPE code did not show any significant difference for calculations in centimetric beams, for a single microbeam and for a microbeam array. The comparisons between penMRT and Gate as an independent MC code did not show any difference in the beam paths, whereas, in valley regions, relative differences between the two codes rank from 1% to 7.5% which are probably due to the differences in physics lists that are used in these two codes. The reliability of the source replication approach has also been tested and validated with an underestimation of no more than 0.6% in low‐dose areas.Conclusions: Good agreements (a relative difference between 0% and 8%) were found when comparing calculated peak to valley dose ratio values using penMRT, for irradiations with a full microbeam array, with calculated values in the literature. The high‐resolution calculated dose maps obtained with penMRT are used to extract differential and cumulative dose–volume histograms (DVHs) and analyze treatment plans with much finer metrics regarding the irradiation complexity. To our knowledge, these are the first high‐resolution dose maps and associated DVHs ever obtained for cross‐fired microbeams irradiation, which is bringing a significant added value to the field of treatment planning in spatially fractionated radiation therapy.
- 12 April 2022
- Published by Wiley in Medical Physics
- Vol. 49 (6) , 3999-4017
Open AccessA high‐resolution dose calculation engine for X‐ray microbeams radiation therapy
Background: Microbeam radiation therapy (MRT) is a treatment modality based on spatial fractionation of synchrotron generated X‐rays into parallel, high dose, microbeams of a few microns width. MRT is still an underdevelopment radiosurgery technique for which, promising preclinical results on brain tumors and epilepsy encourages its clinical transfer.Purpose: A safe clinical transfer of MRT needs a specific treatment planning system (TPS) that provides accurate dose calculations in human patients, taking into account the MRT beam's properties (high‐dose gradients, spatial fractionation, polarization effects). So far, the most advanced MRT TPS, based on a hybrid dose calculation algorithm, is limited to a macroscopic rendering of the dose and does not account for the complex dose distribution inherent to MRT if delivered as conformal irradiations with multiple incidences. For overcoming these limitations, a multi‐scale full Monte‐Carlo calculation engine called penMRT has been developed and benchmarked against two general‐purpose Monte Carlo (MC) codes: penmain based on PENELOPE and Gate based on Geant4.Methods: PenMRT, is based on the PENELOPE (2018) MC code, modified to take into account the voxelized geometry of the patients (computed tomography [CT]‐scans) and is offering an adaptive micrometric dose calculation grid independent of the CT size, location, and orientation. The implementation of the dynamic memory allocation in penMRT, makes the simulations feasible within a huge number of dose scoring bins. The possibility of using a source replication approach to simulate arrays of microbeams, and the parallelization using OpenMPI have been added to penMRT in order to increase the calculation speed for clinical usages. This engine can be implemented in a TPS as a dose calculation core.Results: The performance tests highlight the reliability of penMRT to be used for complex irradiation conditions in MRT. The benchmarking against a standard PENELOPE code did not show any significant difference for calculations in centimetric beams, for a single microbeam and for a microbeam array. The comparisons between penMRT and Gate as an independent MC code did not show any difference in the beam paths, whereas, in valley regions, relative differences between the two codes rank from 1% to 7.5% which are probably due to the differences in physics lists that are used in these two codes. The reliability of the source replication approach has also been tested and validated with an underestimation of no more than 0.6% in low‐dose areas.Conclusions: Good agreements (a relative difference between 0% and 8%) were found when comparing calculated peak to valley dose ratio values using penMRT, for irradiations with a full microbeam array, with calculated values in the literature. The high‐resolution calculated dose maps obtained with penMRT are used to extract differential and cumulative dose–volume histograms (DVHs) and analyze treatment plans with much finer metrics regarding the irradiation complexity. To our knowledge, these are the first high‐resolution dose maps and associated DVHs ever obtained for cross‐fired microbeams irradiation, which is bringing a significant added value to the field of treatment planning in spatially fractionated radiation therapy.